Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Despina Fotiou

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
Hemasphere|March 4, 2024
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patientsMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
European Journal of Haematology|May 23, 2023
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapiesDespina Fotiou, Foteini Theodorakakou, Maria Gavriatopoulou, et al.
The Journal of Infection|May 16, 2021
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative reviewEleni Korompoki, Maria Gavriatopoulou, Rachel S Hicklen, et al.
British Journal of Haematology|February 7, 2024
Thrombotic and bleeding complications in patients with AL amyloidosisDespina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, et al.
British Journal of Haematology|August 15, 2023
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapyFoteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2025
Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center ExperienceIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, et al.
Blood|December 5, 2025
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myelomaEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Leukemia & Lymphoma|January 11, 2019
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsMaria Gavriatopoulou, Despina Fotiou, Ursula Koloventzou, et al.
Blood Cancer Journal|September 26, 2020
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple MyelomaMaria Gavriatopoulou, Andriani Βoultadaki, Vassilis Koutoulidis, et al.
Blood Advances|September 16, 2021
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective studyMaria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
Hemasphere|March 4, 2024
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patientsMaria Papatsirou, Christos K Kontos, Ioannis Ntanasis-Stathopoulos, et al.
European Journal of Haematology|May 23, 2023
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapiesDespina Fotiou, Foteini Theodorakakou, Maria Gavriatopoulou, et al.
The Journal of Infection|May 16, 2021
Epidemiology and organ specific sequelae of post-acute COVID19: A narrative reviewEleni Korompoki, Maria Gavriatopoulou, Rachel S Hicklen, et al.
British Journal of Haematology|February 7, 2024
Thrombotic and bleeding complications in patients with AL amyloidosisDespina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, et al.
British Journal of Haematology|August 15, 2023
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapyFoteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2025
Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center ExperienceIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, et al.
Blood|December 5, 2025
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myelomaEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Leukemia & Lymphoma|January 11, 2019
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsMaria Gavriatopoulou, Despina Fotiou, Ursula Koloventzou, et al.
Blood Cancer Journal|September 26, 2020
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple MyelomaMaria Gavriatopoulou, Andriani Βoultadaki, Vassilis Koutoulidis, et al.
Blood Advances|September 16, 2021
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective studyMaria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
Pageof 11